mosunetuzumab,bortezomib
roche
['fil,veral,12', 'mosunetuzumab', 'lymsm']
mosun monorx r/r fl, longer fu - bartlett
- 8-17 cycles only (response-adap), 3 wkly
- 28.3mo fu, n=90, med 3 prior, 53% double refract
- orr/crr 78%/60%, med dor/docr nr
- 24mo dor 53%, doubles pfs to prior line
- crs mainly low grade
again impressive. #ash22 #lymsm 
Associate Professor of Haematology and lymphoma specialist at Oxford Cancer and Haematology centre. Christian, husband and father.